NCT07060417Not yet recruitingPhase 2
Vascular Effects of SGLT2i in Non-diabetic CKD
The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKD
Source: ClinicalTrials.gov · Last updated 20 Aug 2026
Brief summary (registry, in English)
Empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is a novel diabetic medication that reduces the risk of progression of chronic kidney disease (CKD) and heart failure and improves exercise tolerance regardless of the diabetes status. One of the important ways that empagliflozin improves health may be through its benefits on blood vessels. The effects of empagliflozin on blood vessels and physical function have not been examined in patients with chronic kidney disease, and it is less clear if empagliflozin may be beneficial in patients with chronic kidney disease without heavy urinary protein leakage. The investigators will examine if empagliflozin can improve blood vessel function and exercise tolerance in Veterans with chronic kidney disease without heavy urinary protein leakage.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- First submitted
- 1 Jul 2025
- Start date
- 1 Oct 2026
- Primary completion date
- 31 Mar 2029
- Lead sponsor
- VA Office of Research and Development
- Diseases
- Chronic kidney disease
- NCT number
- NCT07060417
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 52
- From 1 Oct 2026 to the primary completion date, 31 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- expected to start dialysis or receive kidney transplantation or die within 4 months
- extremity skin ulceration requiring active therapy
Other illness
- Type 1 or 2 diabetes mellitus
- infections requiring intravenous antibiotic treatment
- malignancy requiring systemic therapy
- history of Fournier's gangrene
- known allergy to empagliflozin
Lab values
- prior therapy with SGLT2i (Sodium-Glucose Co-Transporter 2 inhibitors) within the previous year
Other
- unable to participate in the physical function tests (hand grip, walk)
- severe hypoglycemia requiring external assistance within the past one year
- pregnancy
Who the study is looking for
- eGFR (estimated glomerular filtration rate) 20-59 mL/min (milliliters per minute)
- albuminuria \<300 mg/g (milligrams per gram)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| VA Salt Lake City Health Care System, Salt Lake City, UT Coordinator of this site? Confirm its status | Salt Lake City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.